IceCure Medical Announces The Publication Of An Independent Study Titled 'Post-Treatment Patient Satisfaction In Early-Stage Breast Cancer: Comparison Of Cryoablation Versus Breast Conservation Therapy Using BREAST-Q' In The Peer Reviewed Journal Gland Surgery

• Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma
• Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean follow-up of 4.2 and 4.0 years, respectively
• Data support continued move toward de-escalation of breast cancer treatment from BCT (lumpectomy) to nonsurgical options including cryoablation

CAESAREA, Israel, March 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled 'Post-treatment patient satisfaction in early-stage breast cancer: Comparison of cryoablation versus breast conservation therapy using BREAST-Q' in the peer reviewed journal Gland Surgery. The study was conducted at the Breast Center, Kameda Medical Center in Kamogawa, Chiba, Japan by the co-authors of the article, Dr. Kizuki Matsumoto, Dr. Yuko Asano, Dr. Hiroki Matsui, and Dr. Eisuke Fukuma. A leading expert and breast surgeon, Dr. Eisuke Fukuma has performed over 600 ProSense® breast cryoablation procedures, has presented on ProSense® and has trained other doctors at medical conferences.

In Japan, the de-escalation of treatment for breast cancer continues, with breast-conserving therapy ("BCT"), typically defined as standard of care breast surgery or lumpectomy, representing approximately 60% of all breast cancer cases, as novel nonsurgical options have emerged.